Alvotech Enrolls First Patient in Clinical Phase III Study Involving Biosimilar Version of HUMIRA(R)
Alvotech's AVT02 is being developed as a biosimilar of the HUMIRA® high-concentration (100mg/mL) product, expected to be more convenient for patients, compared to biosimilar competitors 400 participants to be enrolled in Phase III study at 30 sites ... Biopharmaceuticals, Generics, Dermatology Alvotech, HUMIRA, biosimilar, plaque psoriasis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 13, 2019 Category: Pharmaceuticals Source Type: news

Book Review: Living Light:  The Art of Using Light for Health & Happiness
While it’s hard not to notice the brilliant display of colors set off by a sunset over the water, we seldom consider the biological, or even psychological, benefits of light. “It is my belief that good quality light in our daily lives is far more important than we might think,” writes Karl Ryberg. In his new book, Living Light: The Art of Using Light For Health And Happiness, Ryberg brings us his life’s work — studying the obvious and not so obvious ways in which light affects us and how we can use light in our lives not only function better, but feel better. Light, we know, plays an important...
Source: Psych Central - March 10, 2019 Category: Psychiatry Authors: Claire Nana Tags: Book Reviews Disorders General Habits Psychology Seasonal Affective Disorder Self-Help Treatment artificial light Light therapy Living Light natural light Ryberg SAD Source Type: news

‘Patient-Controlled’ Injector Approved for Tremfya
Patients now have another option for injecting Tremfya—a drug-delivery device designed specifically for patients. FDA has approved Tremfya One-Press, a single-dose, patient-controlled injector for adults with moderate-to-severe plaque psoriasis. TREMFYA is given as a 100-mg subcutaneous injection once every 8 weeks, after starter doses at weeks 0 and 4, Janssen Pharmaceutical Companies of Johnson & Johnson reported. Tremfya One-Press may be used by patients for self-injection with doctor approval and proper training, it was reported. West Pharmaceutical Services Inc. supplied the device. O...
Source: MDDI - March 9, 2019 Category: Medical Devices Authors: Daphne Allen Tags: Design Source Type: news

Durable Urticaria Control With Anti-IgE Drug
(MedPage Today) -- BTK inhibitor for pemphigus, anti-IL-36 drug for pustular psoriasis show early promise at AAD (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - March 7, 2019 Category: Primary Care Source Type: news

When Not to Use Biologics for Psoriasis
(MedPage Today) -- Comorbidities, special populations, idiosyncrasies influence decisions (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 6, 2019 Category: American Health Source Type: news

NEJM-IL-36-Phase-1-GPP-data
Novel antibody shows potential to transform treatment of rare form of psoriasisPublished in The New England Journal of Medicine, new data show single dose BI 655130* rapidly cleared symptoms of a rare and potentially life-threatening form of pustular psoriasis1BI 655130 is an investigational, potential first-in-class treatment targeting interleukin-36 receptor (IL-36R)BI 655130 is being studied in generalised pustular psoriasis as the first of several potential indications, including inflammatory bowel diseases  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 6, 2019 Category: Research Source Type: news

UCLA-led study could point to ways to better control inflammation in autoimmune diseases
In autoimmune diseases such as psoriasis or lupus, the immune system goes into overdrive in response to people ’s own DNA being released from damaged cells — a reaction that can cause severe inflammation in the body.Until now, the molecular processes behind that immune response have not been fully understood by scientists, but a new UCLA-led study could help change that.Researchers at UCLA and three other institutions discovered that LL37 molecules, which are found in the immune system, play an important but unexpected role in revving up the body ’s self-defense response. The finding may bring scientists ...
Source: UCLA Newsroom: Health Sciences - March 5, 2019 Category: Universities & Medical Training Source Type: news

Durable Psoriasis Responses With Dual IL-17 Inhibition
(MedPage Today) -- PASI90/100 responses maintained to 60 weeks with bimekizumab (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - March 5, 2019 Category: Dermatology Source Type: news

Glucose Metabolism in Patients With Psoriasis Glucose Metabolism in Patients With Psoriasis
This study aimed to elucidate the pathophysiological link between psoriasis, glucose metabolism, and T2DM.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 4, 2019 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Novartis data confirm rapid response and high efficacy of Cosentyx ® in psoriasis patients for first time in China
Novartis announced today new data in 441 Chinese patients with moderate to severe plaque psoriasis from a Phase III study investigating the efficacy and safety of Cosentyx (secukinumab). The data, part of a broader ongoing 52 week Phase III study in 543 patients, show 97.7% of patients treated with Cosentyx 300mg achieved PASI 75 and 80.9% achieved PASI 90 by week 12, with 87% of patients reaching PASI 90 by week 16. (Source: World Pharma News)
Source: World Pharma News - March 4, 2019 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Navigating the Biological Maze in Psoriasis
(MedPage Today) -- Higher response rates with newer drugs but older ones still provide good results (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - March 3, 2019 Category: Dermatology Source Type: news

Novel Agent Reduces Severe Pruritus in Psoriasis Novel Agent Reduces Severe Pruritus in Psoriasis
Serlopitant, an oral neurokinin-1 receptor antagonist, blocks the sensation of itch in the brain and reduces pruritus associated with psoriasis, new phase 2 research shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 2, 2019 Category: Consumer Health News Tags: Dermatology News Source Type: news

EU Panel Backs Risankizumab (Skyrizi) for Plaque Psoriasis EU Panel Backs Risankizumab (Skyrizi) for Plaque Psoriasis
The interleukin-23 inhibitor is for treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 1, 2019 Category: Consumer Health News Tags: Dermatology News Alert Source Type: news

Age, Race Impact Atherosclerotic Risk With Psoriasis
FRIDAY, March 1, 2019 -- Some subgroups of patients with psoriasis are at greater risk for atherosclerotic cardiovascular disease (ASCVD), according to a research letter published online Feb. 20 in JAMA Dermatology. Kathryn A. Arnold, from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 1, 2019 Category: Pharmaceuticals Source Type: news

AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI™) for the Treatment of Moderate to Severe Plaque Psoriasis
CHMP positive opinion, supported by data from the pivotal Phase 3 program evaluating more than 2,000 patients with moderate to severe plaque psoriasis, will now be reviewed by the European Commission(1-3) In Phase 3 trials, risankizumab achieved signifi... Biopharmaceuticals, Dermatology, Regulatory AbbVie, SKYRIZI, risankizumab, plaque psoriasis, psoriasis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 1, 2019 Category: Pharmaceuticals Source Type: news

AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI(TM)) for the Treatment of Moderate to Severe Plaque Psoriasis
CHMP positive opinion, supported by data from the pivotal Phase 3 program evaluating more than 2,000 patients with moderate to severe plaque psoriasis, will now be reviewed by the European Commission(1-3) In Phase 3 trials, risankizumab achieved signifi... Biopharmaceuticals, Dermatology, Regulatory AbbVie, SKYRIZI, risankizumab, plaque psoriasis, psoriasis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 1, 2019 Category: Pharmaceuticals Source Type: news

New Guidelines Address Management and Treatment of Psoriasis New Guidelines Address Management and Treatment of Psoriasis
Two new joint American Academy of Dermatology-National Psoriasis Foundation guidelines address the management and treatment of psoriasis in adults, focusing on biologics and on comorbidities.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 27, 2019 Category: Consumer Health News Tags: Medscape Today News Source Type: news

Nervous about needles? FDA OKs Janssen injection device for the squeamish
The Food and Drug Administration on Wednesday granted marketing approval to Janssen Pharmaceutical Co.'s Tremfya One-Press, a patient-controlled injector designed for people with moderate-to-severe psoriasis. Tremfya is Horsham-based Janssen Biotech's biologic treatment approved by the FDA in 2017 for psoriasis, a chronic inflammatory disorder that results in the overproduction of skin cells. The condition causes raised, inflamed, red lesions or plaques — which can result in physical pain and… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 27, 2019 Category: Pharmaceuticals Authors: John George Source Type: news

Janssen Announces U.S. FDA Approval of Novel TREMFYA ® (guselkumab) One-Press Patient-controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 27, 2019 Category: Pharmaceuticals Source Type: news

Persistence of Treatment With Biologics in Psoriasis Persistence of Treatment With Biologics in Psoriasis
Do biologics used in the treatment of psoriasis retain their effectiveness over the long-term?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 27, 2019 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

FDA Approves Tremfya (guselkumab) One-Press Patient-Controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis
HORSHAM, PENNSYLVANIA, February 27, 2019 - The Janssen Pharmaceutical Companies of Johnson& Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya One-Press, a single-dose, patient-controlled injector for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 27, 2019 Category: Drugs & Pharmacology Source Type: news

Psoriasis Effects on CV Risk May be Direct and Vary by Race Psoriasis Effects on CV Risk May be Direct and Vary by Race
' It may still be an independent effect of the psoriasis, but acting through these other traditional risk factors,'said a researcher. Younger African-American adults seemed to be at special risk.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 25, 2019 Category: Dermatology Tags: Cardiology News Source Type: news

Guideline Covers Extracutaneous Manifestations of Psoriasis
FRIDAY, Feb. 22, 2019 -- The extracutaneous manifestations of psoriasis and guidance on use of biologic treatment for management of psoriasis are discussed in two new guidelines published online Feb. 13 in the Journal of the American Academy of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 22, 2019 Category: Pharmaceuticals Source Type: news

What Is the Best Treatment for Psoriasis?
Title: What Is the Best Treatment for Psoriasis?Category: Diseases and ConditionsCreated: 2/20/2019 12:00:00 AMLast Editorial Review: 2/22/2019 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - February 22, 2019 Category: Dermatology Source Type: news

5 Noteworthy Cardiovascular Studies from American Heart Month
Psoriasis medication for heart disease prevention, the role of artificial sweeteners in different types of stroke, and 3 other noteworthy findings from American Heart Month.   (Source: ConsultantLive)
Source: ConsultantLive - February 20, 2019 Category: Internal Medicine Authors: Sydney Jennings Tags: Cardiovascular Source Type: news

Clarify Medical wins CMS reimbursement for phototherapy psoriasis treatment
Clarify Medical said today that it won reimbursement coverage through the U.S. Centers for Medicare & Medicaid Services for treatments with its Clarify Home light therapy system for treating psoriasis, effective immediately. The new decision from CMS falls under its National Coverage Determination for the treatment of psoriasis, which includes narrowband ultraviolet B phototherapy, San Diego-based Clarify Medical said. The company’s Clarify system uses narrowband ultraviolet B rays to penetrate the skin and slow the growth of affected skin cells. Studies have found that narrowband UVB rays help to clear psoriasis...
Source: Mass Device - February 12, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Cosmetic/Aesthetic Clarify Medical Source Type: news

Psoriasis Tx Linked to Drop in Noncalcified Coronary Plaque
WEDNESDAY, Feb. 6, 2019 -- Treatment of psoriasis with biologic therapy is associated with a reduction in noncalcified coronary plaque and improved plaque morphology, according to a study published online Feb. 5 in Cardiovascular Research. Youssef... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 6, 2019 Category: Pharmaceuticals Source Type: news

Medical News Today: Immunosuppressants reduce artery plaque in people with psoriasis
New research finds that a psoriasis treatment that suppresses the immune system can improve the cardiovascular health of those living with psoriasis. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 6, 2019 Category: Consumer Health News Tags: Psoriasis Source Type: news

Biologic Tx for Psoriasis Tied to Better Heart Health
(MedPage Today) -- Treatment linked with non-calcified coronary plaque reduction, plaque morphology improvement (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 6, 2019 Category: Cardiology Source Type: news

Psoriasis Meds Might Help Fight Heart Trouble, Too
The use of inflammation-suppressing drugs known as biologics appeared to be linked with a slowed buildup of fatty plaques in arteries in a recent study. (Source: WebMD Health)
Source: WebMD Health - February 5, 2019 Category: Consumer Health News Source Type: news

Study links psoriasis treatment and improvement in heart artery disease
Biologic drugs that target immune system activity can reduce the early plaque buildup that clogs arteries. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - February 5, 2019 Category: American Health Source Type: news

Psoriasis Meds Might Help Fight Heart Trouble, Too
TUESDAY, Feb. 5, 2019 -- Could the inflammation that drives psoriasis and other immune-linked illnesses be a major player in heart disease? In a new study, certain psoriasis drugs appeared to help to keep arteries clear, suggesting such a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 5, 2019 Category: General Medicine Source Type: news

Psoriasis Meds Might Help Fight Heart Trouble, Too
Title: Psoriasis Meds Might Help Fight Heart Trouble, TooCategory: Health NewsCreated: 2/5/2019 12:00:00 AMLast Editorial Review: 2/5/2019 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - February 5, 2019 Category: Cardiology Source Type: news

Psoriasis medication may improve heart disease in patients with the skin condition
(European Society of Cardiology) Anti-inflammatory biologic drugs used to treat severe psoriasis have the potential to prevent heart disease in patients with the skin condition, according to research published today in Cardiovascular Research, a journal of the European Society of Cardiology (ESC). During one year of treatment, biologic therapy improved coronary artery plaque similar to the effect of a low-dose statin. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 5, 2019 Category: International Medicine & Public Health Source Type: news

Study links psoriasis treatment and improvement in heart artery disease
(NIH/National Heart, Lung and Blood Institute) Researchers have found that treating psoriasis, a chronic inflammatory skin disease, with biologic drugs that target immune system activity can reduce the early plaque buildup that clogs arteries, restricts blood flow, and leads to heart attacks and stroke. The findings highlight how immunotherapies that treat inflammatory conditions might play a role in the reduction of cardiovascular disease risks. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 5, 2019 Category: International Medicine & Public Health Source Type: news

Tremfya and Ilymya listed for plaque psoriasis in Australia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2019 Category: Drugs & Pharmacology Source Type: news

Celgene profit beats as psoriasis drug sales surge
Celgene Corp, which is being bought by Bristol-Myers Squibb Co, reported a better-than-expected fourth-quarter profit on Thursday, driven mainly by higher sales of psoriasis drug Otezla. (Source: Reuters: Health)
Source: Reuters: Health - January 31, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Methotrexate Well Tolerated, Effective for Psoriasis in Chinese
THURSDAY, Jan. 31, 2019 -- Methotrexate is well tolerated and effective for psoriasis in a Chinese population and is more effective for those without psoriatic arthritis, according to a study published online Jan. 30 in JAMA Dermatology. Kexiang... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 31, 2019 Category: Pharmaceuticals Source Type: news

FDA approves J & J ’s Tremfya self-injection pen for psoriasis
FDA has approved Johnson & Johnson’s patient-controlled injector for Tremfya, a treatment for adults with moderate to severe plaque psoriasis. The self-injection approval may help Tremfya compete with AbbVie’s (NYSE:ABBV) Humira pen, which was previously approved for self-injection by psoriasis patients. Get the full story on our sister site, Drug Delivery Business. The post FDA approves J&J’s Tremfya self-injection pen for psoriasis appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 30, 2019 Category: Medical Devices Authors: Nancy Crotti Tags: Blog Drug-Device Combinations Food & Drug Administration (FDA) News Well AbbVie Janssen Pharmaceuticals johnsonandjohnson Source Type: news

IBD Risk Low in Patients Taking Secukinumab (CME/CE)
(MedPage Today) -- IBD events rare across 21 clinical trials for patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis given the agent (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - January 29, 2019 Category: Dermatology Source Type: news

Treat psoriasis naturally with vitamin D and zinc
(Natural News) Psoriasis is a chronic skin problem that affects over 7.5 million Americans. The condition can result in complications ranging from arthritis, cardiovascular disease, and even depression; however, a study from Al-Furat Al-Awsat University in Iraq suggests that these complications could also cause a decline of nutrients needed to battle the condition. In their... (Source: NaturalNews.com)
Source: NaturalNews.com - January 27, 2019 Category: Consumer Health News Source Type: news

IBD Rates Low in Patients on Cosentyx
(MedPage Today) -- Analysis of data from 21 clinical trials in psoriasis, psoriatic arthritis, and ankylosing spondylitis (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - January 25, 2019 Category: Dermatology Source Type: news

South Jersey pharma firm gets FDA approval for generic skin cream
Teligent Inc., a New Jersey-based specialty generic pharmaceutical company, announced Thursday it has received approval for its abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration. The FDA approved the ANDA for a skin disorder treatment called clobetasol propionate ointment from Teligent, a South Jersey specialty generic pharmaceutical company. The cream is used to treat a variety of skin disorders including eczema and psoriasis and for contact dermatitis caused by… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 24, 2019 Category: Biotechnology Authors: John George Source Type: news

Medical News Today: Which herbs can help with psoriasis?
Herbs have a long history in the treatment of skin conditions. Recent review studies suggest that certain herbs can help with the symptoms of psoriasis. In this article, we look at the effectiveness and side effects of herbs and other plant treatments for psoriasis. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 24, 2019 Category: Consumer Health News Tags: Psoriasis Source Type: news

Medical News Today: Which skin conditions can mimic psoriasis?
Several skin conditions can have similar symptoms to psoriasis, and this can lead to a misdiagnosis. Learn about other conditions that look like psoriasis, and tips for getting the right diagnosis, here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 18, 2019 Category: Consumer Health News Tags: Psoriasis Source Type: news

Medical News Today: How are psoriasis and HIV related?
Doctors estimate that 1 to 3 percent of people with HIV also have psoriasis. In this article, we explore the link between the two, and how the treatments for HIV and psoriasis might interact. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 17, 2019 Category: Consumer Health News Tags: Psoriasis Source Type: news

Psoriasis | Medscape Psoriasis | Medscape
Review clinical reference information, guidelines, and medical news on psoriasis--including psoriasis symptoms and psoriasis treatment. Recognize psoriasis arthritis (psoriatic arthritis), scalp psoriasis, psoriasis vulgaris, and pustular psoriasis. (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 17, 2019 Category: Consumer Health News Tags: Resource Center Source Type: news

Medical News Today: Does biotin help with psoriasis?
Some people use supplements of biotin, or vitamin B-7, to manage the symptoms of psoriasis. In this article, we look at the effectiveness, risks, and alternatives to biotin for psoriasis. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 17, 2019 Category: Consumer Health News Tags: Psoriasis Source Type: news

Medical News Today: What to know about psoriasis remission
Psoriasis symptoms tend to come and go in periods of flares and remission. In this article, we discuss what to expect from psoriasis remission and how to prevent or reduce psoriasis flares. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 16, 2019 Category: Consumer Health News Tags: Psoriasis Source Type: news

Medical News Today: Can tamanu oil help with psoriasis?
Tamanu oil is a traditional remedy for various skin conditions. In this article, we look at the effectiveness of tamanu oil for treating psoriasis. We also consider the other uses and possible risks of this oil and provide alternative natural treatment options. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - January 16, 2019 Category: Consumer Health News Tags: Psoriasis Source Type: news